Emerging roles of human prostatic acid phosphatase

Biomolecules and Therapeutics

Volumn 21, Issue 1, 2013, Pages 10-20

  Kong, Hoon Young ^a   Byun, Jonghoe ^a  

^a Dankook University   (South Korea)

Author keywords

Biomarker; Diagnosis; Immunotherapy; Prognosis; Prostate cancer; Prostatic acid phosphatase (PAP)

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; AMYLOID; CELLULAR ACID PHOSPHATASE PROSTATE ISOENZYME; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B; SECRETORY FORM ACID PHOSPHATASE PROSTATE ISOENZYME; SEMEN DERIVED ENHANCER OF VIRUS INFECTION; SIPULEUCEL T; UNCLASSIFIED DRUG;

ANTINOCICEPTION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; DISEASE ASSOCIATION; DISEASE MARKER; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HIGH RISK PATIENT; HUMAN; INFLAMMATORY PAIN; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; NEUROPATHIC PAIN; NONHUMAN; OLIGOSPERMIA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; VIRUS TRANSMISSION;

EID: 84873343419     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2012.095     Document Type: Review

References (109)

1. Abrahamsson, P. A., Lilja, H., Falkmer, S. and Wadström, L. B. (1988) Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 12, 39-46.
2. Afzal, S., Ahmad, M., Mushtaq, S., Mubarik, A., Qureshi, A. H. and Khan, S. A. (2003) Morphological features correlation with serum tumor markers in prostatic carcinoma. J. Coll. Physicians. Surg. Pak. 13, 511-514.
3. Antonarakis, E. S. and Drake, C. G., (2010) Current status of immunological therapies for prostate cancer. Curr. Opin. Urol. 20, 241-246.
4. Azumi, N., Traweek, S. T. and Battifora, H. (1991) Prostatic acid phosphatase in carcinoid tumors: Immunohistochemical and immunoblot studies. Am. J. Surg. Pathol. 15, 758-790.
5. Batta, A., Panag, KMDS. and Singh, J. (2012) Diagnosis of prostatecancer --- Role of biomarkers. Int. J. Cur. Biomed. Phar. Res. 2,339-345.
6. Becker, C., Piironen, T., Pettersson, K., Björk, T., Wojno, K. J., Oesterling, J. E. and Lilja, H. (2000) Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J. Urol. 163, 311-316.
7. Brawer, M. K., Chetner, M. P., Beatie, J., Buchner, D. M., Vessella, R. L. and Lange, P. H. (1992) Screening for prostatic carcinoma with prostate specific antigen. J. Urol. 147, 841-845.
8. Bussemakers, M. J., van Bokhoven, A., Verhaegh, G. W., Smit, F. P., Karthaus, H. F., Schalken, J. A., Debruyne, F. M., Ru, N. and Isaacs, W. B. (1999) DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 59, 5975-5979.
9. Cheever, M. A. and Higano, C. S. (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520-3526.
10. Chen, H., Pong, R. C., Wang, Z. and Hsieh, J. T. (2002) Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization. Genomics 79, 573-581.
11. Collins, K. A. and Bennett, A. T. (2011) Persistence of spermatozoa and prostatic acid phosphatase in specimens from decreased individuals during varied postmortem intervals. Am. J. Forensic Med. Pathol. 22, 228-232.
12. Coussens, L. M. and Werb, Z. (2002) Inflammation and cancer. Nature 420, 860-867.
13. Dave, B. N. and Rindani, T. H. (1988) Acid phosphatase activity in human semen. Int. J. Fertil. 33, 45-47.
14. Deftos, L. J. (1998) Granin-A, parathyroid hormone-related protein, and calcitonin gene products in neuroendocrine prostate cancer. Prostate Suppl. 8, 23-31.
15. Drake, C. G. (2010) Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 10, 580-593
16. Drake, C. G. (2012) Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl. Cancer Inst. 104, 1422.
17. Erbas, H., Erten, O. and Irfanoglu, M. E. (2007) Prostatic acid phosphatase in breast cyst fluid. Malays. J. Pathol. 29, 95-99.
18. Ercole, C. J., Lange, P. H., Mathisen, M., Chiou, R. K., Reddy, P. K. and Vessella, R. L. (1987) Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer. J. Urol. 138, 1181-1184.
19. Fang, L.C., Dattoli, M., Taira, A., True, L., Sorace, R. and Wallner K. (2008) Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy. Urology 71, 146-150.
20. Garcia, J. A. (2011) Sipuleucel-T in patients with metastatic castrationresistant prostate cancer: an insight for oncologists. Ther. Adv. Med. Oncol. 3, 101-108.
21. Gerdes, J., Lemke, H., Baisch, H., Wacker, H. H., Schwab, U. and Stein, H. (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133, 1710-1715.
22. Gerritsen, W. R. (2012) The evolving role of immunotherapy in prostate cancer. Ann. Oncol. 23, viii22-27.
23. Getzenberg, R. H., Pienta, K. J., Huang, E. Y. and Coffey, D. S. (1991) Identification of nuclear matrix proteins in the cancer and normal rat prostate. Cancer Res. 51, 6514-6520.
24. Goldfarb, D. A., Stein, B. S., Shamszadeh, M. and Petersen, R. O. (1986) Age-related changes in tissue level of prostatic acid phosphatase and prostate specific antigen. J. Urol. 136, 1266-1269.
25. Graddis, T. J., McMahan, C. J., Tamman, J., Page, K. J. and Trager, J. B. (2011) Prostatic acid phosphatase expression in human tissues. Int. J. Clin. Exp. Pathol. 4, 295-306.
26. Gunia, S., Koch, S., May, M., Dietel, M. and Erbersdobler, A. (2009) Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies. Virchows. Arch. 454, 573-579.
27. Gupta, A., Lotan, Y., Ashfaq, R., Roehrborn, C. G., Raj, G. V., Aragaki, C. C., Montorsi, F. and Shariat, S. F. (2009) Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur. Urol. 55, 1124-1133.
28. Gutman, A. B. and Gutman, E. B. (1938) An "acid" phosphatase occur ring in the serum of patients with metastasizing carcinoma of the prostate gland. J. Clin. Invest. 17, 473-478.
29. Harvey, A. M., Grice, B., Hamilton, C., Truong, L. D., Ro, J. Y., Ayala, A. G. and Zhai, Q. J. (2010) Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b. Arch. Pathol. Lab. Med. 134, 983-988.
30. Hassan, M. I., Aijaz, A. and Ahmad, F. (2010) Structural and functional analysis of human prostatic acid phosphatase. Expert. Rev. Anticancer Ther. 10, 1055-1068.
31. Hobisch, A., Eder, I. E., Putz, T., Horninger, W., Bartsch, G., Klocker, H. and Culig Z. (1998) Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 58, 4640-4645.
32. Hong, S., Klein, E. A., Das Gupta, J., Hanke, K., Weight, C. J., Nguyen, C., Gaughan, C., Kim, K. A., Bannert, N., Kirchhoff, F., Munch, J. and Silverman, R. H. (2009) Fibrils of prostatic acid phosphatase fragments boost infections with XMRV (xenotropic murine leukemia virus-related virus), a human retrovirus associated with prostate. J. Virol. 83, 6995-7003.
33. Hsing, A. W. and Chokkalingam, A. P. (2006) Prostate cancer epidemiology. Front. Biosci. 11, 1388-1413.
34. Huang, C. L., Brassil, D., Rozzell, M., Schellhammer, P. F. and Wright, G. L. Jr. (1993) Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma. Prostate 23, 201-212.
35. Hubert, R. S., Vivanco, I., Chen, E., Rastegar, S., Leong, K., Mitchell, S. C., Madraswala, R., Zhou, Y., Kuo, J., Raitano, A. B., Jakobovits, A., Saffran, D. C. and Afar, D. E. (1999) STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc. Natl. Acad. Sci. USA 96, 14523-14528.
36. Hurt, J. K., Fitzpatrick, B. J. Norris-Drouin, J. and Zylka, M. J. (2012a) Secretion and N-linked glycosylation are required for prostatic acid phosphatase catalytic and antinociceptive activity. PLoS One 7, e32741.
37. Hurt, J. K. and Zylka, M. J. (2012b) PAPupuncture has localized and long-lasting antinociceptive effects in mouse models of acute and chronic pain. Mol. Pain. 8, 28.
38. Jakob, C. G., Lewinski, K., Kuciel, R., Ostrowski, W. and Lebioda, L. (2000) Crystal structure of human prostatic acid phosphatase. Prostate 42, 211-218.
39. Kong, H. Y., Lee, H. J. and Byun, J. (2011) Roles of prostatic acid phosphatase in prostate cancer. J. Life Sci. 21, 893-900.
40. Korkmaz, C. G., Korkmaz, K. S., Kurys, P., Elbi, C., Wang, L., Klokk, T. I., Hammarstrom, C., Troen, G., Svindland, A., Hager, G. L. and Saatcioglu, F. (2005) Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene 24, 4934-4945.
41. Korkmaz, K. S., Elbi, C., Korkmaz, C. G., Loda, M., Hager, G. L. and Saatcioglu, F. (2002) Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer. J. Biol. Chem. 277, 36689-36696.
42. Kraus, T. S., Cohen, C. and Siddiqui, M. T. (2010) Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagn. Pathol. 5, 63.
43. Kristiansen, G., Fritzsche, F. R., Wassermann, K., Jäger, C., Tölls, A., Lein, M., Stephan, C., Jung, K., Pilarsky, C., Dietel, M. and Moch, H. (2008) GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br. J. Cancer 99, 939-948.
44. Kuciel, R., Bakalova, A., Mazurkiewicz, A., Bilska, A. and Ostrowski, W. (1990) Is the subunit of prostatic phosphatase active?Reversible denaturation of prostatic acid phosphatase. Biochem. Int. 22, 329-334.
45. Larne, O., Martens-Uzunova, E., Hagman, Z., Edsjö, A., Lippolis, G., den Berg, M. S., Bjartell, A., Jenster, G. and Ceder, Y. (2012) miQ a novel microRNA based diagnostic and prognostic tool for prostatecancer. Int. J. Cancer doi: 10.1002/ijc.27973. [Epub ahead of print]
46. Lee, H., Chu, T. M., Li, S. S. and Lee, C. L. (1991) Homodimer and heterodimer subunits of human prostatic acid phosphatase. Biochem. J. 277, 759-765.
47. Lee, W. H., Morton, R. A., Epstein, J. I., Brooks, J. D., Campbell, P. A., Bova, G. S., Hsieh, W. S., Isaacs, W. B. and Nelson, W. G. (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 91, 11733-11737.
48. Li, T. S. and Beling, C. G. (1973) Isolation and characterization of two specific antigens of human seminal plasma. Fertil. Steril. 24, 134-144.
49. Lin, M. F., Garcia-Arenas, R., Xia, X. Z., Biela, B. and Lin, F. F. (1994) The cellular level of prostatic acid phosphatase and the growth of human prostate carcinoma cells. Differentiation 57, 143-149.
50. Lin, M. F., Lee, M. S., Zhou, X. W., Andressen, J. C., Meng, T. C., Johansson, S. L., West, W. W., Taylor, R. J., Anderson, J. R. and Lin, F. F. (2001) Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J. Urol. 166, 1943-1950.
51. Lin, M. F., Meng, T. C., Rao, P. S., Chang, C., Schonthal, A. H. and Lin, F. F. (1998) Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J. Biol. Chem. 273, 5939-5947.
52. Liu, B. Q., Wu, Y. D., Li, P. H., Wei, J. X., Zhang, T. and Liu R. L. (2007) Prostate cancer antigen-1 as a potential novel marker for prostate cancer. Asian J. Androl. 9, 821-826.
53. Lubaroff, D. M. (2012) Prostate cancer vaccines in clinical trials. Expert. Rev. Vaccines 11, 857-868.
54. Madu, C. O. and Lu, Y. (2010) Novel diagnostic biomarkers for prostate cancer. J. Cancer 1, 150-177.
55. Makarov, D. V., Loeb, S., Getzenberg, R. H. and Partin, A. W. (2009) Biomarkers for prostate cancer. Ann. Rev. Medicine 60, 139-151.
56. McNeel, D. G., Dunphy, E.J., Davies, J. G., Frye, T. P., Johnson, L. E., Staab, M. J., Horvath, D. L., Straus, J., Alberti, D., Marnocha, R., Liu, G., Eickhoff, J. C. and Wilding, G. (2009) Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with D0 prostate cancer. J. Clin. Oncol. 27, 4047-4054.
57. Meng, T. C., Lee, M. S. and Lin, M. F. (2000) Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene19, 2664-2677.
58. Merrick, G. S., Butler, W. M., Wallner, K. E., Allen, Z., DeFilippo, J. L. and Adamovich, E. (2005) Enzymatic prostatic acid phosphatase in the clinical staging of patients diagnosed with prostate cancer. W. V. Med. J. 101, 116-119.
59. Münch, J., Rücker, E, Ständker, L., Adermann, K., Goffinet, C., Schindler, M., Wildum, S., Chinnadurai, R., Rajan, D., Specht, A., Giménez-Gallego, G., Sánchez, P. C., Fowler, D. M., Koulov, A., Kelly, J. W., Mothes, W., Grivel, J. C., Margolis, L., Keppler, O. T., Forssmann, W. G. and Kirchhoff, F. (2007) Semen-derived amyloid-fibrils drastically enhance HIV infection. Cell 131, 1059-1071.
60. Okar, D. A., Live, D. H., Devany, M. H. and Lange, A. J. (2000) Mechanism of the bisphosphatase reaction of 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase probed by (1)H-(15)N NMR spectroscopy. Biochemistry 39, 9754-9762.
61. Ortlund, E., LaCount, M. W. and Lebioda, L. (2003) Crystal structure of human prostatic acid phosphatase in complex with a phosphate ion and a-benzylaminobenzylphosphonic acid update the mechanistic picture and offer new insight into inhibitor design. Biochemistry 42, 383-389.
62. Ostanin, K., Saeed, A. and Van Etten, R. L. (1994) Heterologous expression of human prostatic acid phosphatase and site-directed mutagenesis of the enzyme active site. J. Biol. Chem. 269, 8971-8978.
63. Ostrowski, W. S. and Kuciel, R. (1994) Human prostatic acid phosphatase: selected properties and practical applications. Clin. Chim. Acta. 226, 121-129.
64. Porvari, K., Kurkela, R., Kivinen, A. and Vihko, P. (1995) Differential androgen regulation of rat prostatic acid phosphatase transcripts. Biochem. Biophys. Res. Commun. 213, 861-868.
65. Quintero, I. B., Araujo, C. L., Pulkka, A. E., Wirkkala, R. S., Herrala, A. M., Eskelinen, E. L., Jokitalo, E., Hellström, P. A., Tuominen, H. J., Hirvikoski, P. P. and Vihko, P. T. (2007) Prostatic acid phosphatase is not a prostate specific target. Cancer Res. 67, 6549-6554.
66. Reif, A. E., Schlesinger, R. M., Fish, C. A. and Robinson, C. M. (1973) Acid phosphatase isoenzymes in cancer of the prostate. Cancer 31, 689-699.
67. Reiter, R. E., Gu, Z., Watabe, T., Thomas, G., Szigeti, K., Davis, E., Wahl, M., Nisitani, S., Yamashiro, J., Le Beau, M. M., Loda, M. and Witte, O. N. (1998) Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 95, 1735-1740.
68. Rogers, C. G., Yan, G., Zha, S., Gonzalgo, M. L., Isaacs, W. B., Luo, J., De Marzo, A. M., Nelson, W. G. and Pavlovich, C. P. (2004) Prostate cancer detection on urinalysis for alpha methylacyl coenzyme A racemase protein. J. Urol. 172, 1501-1503.
69. Roiko, K., Jänne, O. A. and Vihko, P. (1990) Primary structure of rat secretory acid phosphatase and comparison to other acid phosphatase. Gene 89, 223-229.
70. Ronnberg, L., Vihko, P., Sajanti, E. and Vihko, R. (1981). Clomiphene citrate administration to normogonadotrophic subfertile men: blood hormone changes and activation of acid phosphatase in seminal fluid. Int. J. Androl. 4, 372-378.
71. Roth, T. J., Sheinin, Y., Lohse, C. M., Kuntz, S. M., Frigola, X., Inman, B. A., Krambeck, A. E., McKenney, M. E., Karnes, R. J., Blute, M. L., Cheville, J. C., Sebo, T. J. and Kwon, E. D. (2007) B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res. 67, 7893-7900.
72. Rubenstein, M., Hollowell, C. M. and Guinan, P. (2012) Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR. Med. Oncol. 29, 835-841.
73. Saito, T., Hara, N., Kitamura, Y. and Komatsubara, S. (2007) Prostate-specific antigen/ prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer. Urology 70, 702-705.
74. Shan, J., Porvari, K., Kivinen, A., Patrikainen, L., Halmekytö, M., Jänne, J. and Vihko, P. (2003) Tissue-specific expression of the prostatic acid phosphatase promoter constructs. Biochem. Biophys. Res. Commun. 311, 864-869.
75. Shan, J., Porvari, K. and Vihko, P. (2005) GAAAATATGATA-like elements in androgen-associated regulation of the prostatic acid phosphatasegene. J. Steroid. Biochem. Mol. Biol. 96, 245-249.
76. Shariat, S. F., Scherr, D. S., Gupta, A., Bianco, F. J. Jr, Karakiewicz, P. I., Zeltser, I. S., Samadi, D. B. and Akhavan, A. (2011) Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. Arch. Esp. Urol. 64, 681-694.
77. Sharma, S. and Juffer, A. H. (2009) Hydrolysis of phosphohistidine in water and in prostatic acid phosphatase. Chem. Commun (Camb). 14, 6385-6387.
78. Sheftic, S. R., Snell, J. M., Jha, S. and Alexandrescu, A. T. (2012) Inhibition of semen-derived enhancer of virus infection (SEVI) fibrillogenesis by zinc and copper. Eur. Biophys J. 41, 695-704.
79. Sheridan, T., Herawi, M., Epstein, J. I. and Illei, P. B. (2007) The role of P501S and PSA in diagnosis of metastatic adenocarcinoma of the prostate. Am. J. Surg. Pathol. 31, 1351-1355.
80. Sims, R. B. (2012) Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 30, 4394-4397.
81. Singh, G., Adaikan, P. G. and Ng, Y. K. (1996) Is seminal prostatic acid phosphatase a reliable marker for male infertility? Singapore Med. J. 37, 598-599.
82. Small, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A. and Hershberg, R. M. (2006) Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089-3094.
83. Solin, T., Kontturi, M., Pohlmann, R. and Vihko, P. (1990) Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analyses. Biochim. Biophys. Acta. 1048, 72-77.
84. Sowa, N. A., Street, S. E., Vihko, P. and Zylka, M. J. (2010) Pros- tatic acid phosphatase reduces thermal sensitivity and chronic pain sensitization by depleting phosphatidylinositol 4,5-bisphosphate. J. Neurosci. 30, 10282-10293.
85. Sowa, N. A., Vadakkan, K. I. and Zylka, M. J. (2009) Recombinant mouse PAP has pH-dependent ectonucleotidase activity and acts through A(1)-adenosine receptors to mediate antinociception. PLoS One 4, e4248.
86. Sreekumar, A., Poisson, L. M., Rajendiran, T. M., Khan, A. P., Cao, Q., Yu, J., Laxman, B., Mehra, R., Lonigro, R. J., Li, Y., Nyati, M. K., Ahsan, A., Kalyana-Sundaram, S., Han, B., Cao, X., Byun, J., Omenn, G. S., Ghosh, D., Pennathur, S., Alexander, D. C., Berger, A., Shuster, J. R., Wei, J. T., Varambally, S., Beecher, C. and Chinnaiyan, A. M. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457, 910-914.
87. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freiha, F. S. and Redwine, E. (1987) Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317, 909-916.
88. Street, S. E., Walsh, P. L., Sowa, N. A., Taylor-Blake, B., Guillot, T. S., Vihko, P., Wightman, R. M. and Zylka, M. J. (2011) PAP and NT5E inhibit nociceptive neurotransmission by rapidly hydrolyzing nucleotides to adenosine. Mol. Pain 7, 80.
89. Taira, A., Merrick, G., Wallner, K. and Dattoli, M. (2007) Reviving the acid phosphatase test for prostate cancer. Oncology 21, 1003-1010.
90. Taskén, K. A., Angelsen, A., Svindland, A., Eide, T., Berge, V., Wahlquist, R. and Karlsen, S. (2005) Markers for diagnosis, prediction and prognosis of prostate cancer. Tidsskr. Nor. Laegeforen. 125, 3279-3282.
91. Thompson, T. C., Tahir, S. A., Li, L., Watanabe, M., Naruishi, K., Yang, G., Kadmon, D., Logothetis, C. J., Troncoso, P., Ren, C., Goltsov, A. and Park, S. (2010) The role of caveolin-1 in prostate cancer: clinical implications. Prostate Cancer Prostatic. Dis. 13, 6-11.
92. Tian, W., Osawa, M., Horiuchi, H. and Tomita, Y. (2004) Expression of the prolactin-inducible protein (PIP/GCDFP15) gene in benign epithelium and adenocarcinoma of the prostate. Cancer Sci. 95, 491-495.
93. Truong, L. D., Kadmon, D., McCune, B. K., Flanders, K. C., Scardino, P. T. and Thompson, T. C. (1993) Association of transforming growth factor-beta 1 with prostate cancer: An immunohistochemical study. Hum. Pathol. 24, 4-9.
94. Van Etten, R. L. (1982) Human prostatic acid phosphatase: a histidine phosphatase. Ann. N. Y. Acad. Sci. 390, 27-51.
95. Van Etten, R. L., Davidson, R., Stevis, P. E., MacArthur, H. and Moore, D. L. (1991) Covalent structure, disulfide binding, and identification of reactive surface and active site residues of human prostatic acid phosphatase. J. Biol. Chem. 266, 2313-2319.
96. Vanaja, D. K., Ballman, K. V., Morlan, B. W., Cheville, J. C., Neumann, R. M., Lieber, M. M., Tindall, D. J. and Young, C. Y. (2006) PDLIM4 repression by hypermethylation as a potential biomarker for pros tate cancer. Clin. Cancer Res. 12, 1128-1136.
97. Veeramani, S., Yuan, T. C., Chen, S. J., Lin, F. F., Petersen, J. E., Shaheduzzaman, S., Srivastava, S., MacDonald, R. G. and Lin, M. F. (2005) Cellular prostatic acid phosphatase : A protein tyrosine phosphatase involved in androgen-independent proliferation of phosphatase. Endocr. Relat. Cancer 12, 805-822.
98. Vieweg, J. and Dannull, J. (2005) Technology insight: vaccine therapy for prostate cancer. Nat. Clin. Pract. Urol. 2, 44-51.
99. Vihko, P., Herrala, A., Härkönen, P., Isomaa, V., Kaija, H., Kurkela, R., Li, Y., Patrikainen, L., Pulkka, A., Soronen, P. and Törn, S. (2005) Enzymes as modulators in malignant transformation. J. Steroid Biochem. Mol. Biol. 93, 277-283.
100. Vihko, P., Kontturi, M. and Korhonen, L. K. (1978) Purification of human prostatic acid phosphatase by affinity chromatography and isoelectric focusing. Part I. Clin. Chem. 24, 466-470.
101. Wang, Y., Harada, M., Yano, H., Ogasawara, S., Takedatsu, H., Arima, Y., Matsueda, S., Yamada, A. and Itoh, K. (2005) Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J. Immunother. 28, 535-541.
102. Wikström, P., Lissbrant, I. F., Stattin, P., Egevad, L. and Bergh, A. (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 51, 268-275.
103. Winqvist, R., Virkkunen, P., Grzeschik, K. H. and Vihko, P. (1989) Chromosomal localization to 3q21----qter and two TaqI RFLPs of the human prostatic-specific acid phosphatase gene (ACPP). Cytogenet. Cell Genet. 52, 68-71.
104. Young, A., Palanisamy, N., Siddiqui, J., Wood, D. P., Wei, J. T., Chinnaiyan, A. M., Kunju, L. P. and Tomlins, S. A. (2012) Correlation of Urine TMPRSS2:ERG and PCA3 to ERG+ and Total Prostate Cancer Burden. Am. J. Clin. Pathol. 138, 685-696.
105. Zelivianski, S., Comeau, D. and Lin, M. F. (1998) Cloning and analysis of the promoter activity of the human prostatic acid phosphatase gene. Biochem. Biophys. Res. Commun. 245, 108-112.
106. Zelivianski, S., Glowacki, R. and Lin, M. F. (2004) Transcriptional activation of the human prostatic acid phosphatase gene by NF-kB via a novel hexanucleotide-binding site. Nucleic. Acid. Res. 32, 3566-3580.
107. Zhang, X. Q., Lee, M. S., Zelivianski, S. and Lin, M. F. (2001) Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells. J. Biol. Chem. 276, 2544-2550.
108. Zimmermann, H. (2009) Prostatic acid phosphatase, a neglected ectonucleotidase. Purinergic Signal. 5, 273-275
109. Zylka, M. J., Sowa, N. A., Taylor-Blake, B., Twomey, M. A., Herrala, A., Voikar, V. and Vihko P. (2008) Prostatic acid phosphatase is an ectonucleotidase and suppresses pain by generating adenosine. Neuron 60, 111-122.